RxDoctor Payments Data

Leigh Reardon, MD

Pediatric Cardiology · Los Angeles, CANPI 1649200817

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $74,430 of the $86,562 with a category attached, or 86.0%. Actelion Pharmaceuticals US, Inc. accounts for 97.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $21,381 and has fallen 73.7% since, to $5,632 in 2025. Among pediatric cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$86,562in general payments, 2019–2025

Across 162 payments — averaging $534.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$84K
  • Biotronik Inc.$614
  • Eko Health, Inc.$489
  • Abbott$208
  • Paragonix Technologies, Inc.$160
  • Merck$143
  • plus $559 from 6 others

What the payments were for

  • Consulting fees$3,5354%
  • Speaking & faculty fees$74,43086%
  • Travel & lodging$2,2683%
  • Food & beverage$5,7917%
  • Education$1090%
  • Other$4290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$86,562 in reported general payments places this provider in the 95th percentile of 239 pediatric cardiology providers in California.

See all pediatric cardiology providers in California

Medicare billing

Part B allowed, 2024
$40,512
Medicare patients
80
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan34$418,573
UptraviSelexipag13$290,662
TracleerBosentan11$137,564
Tadalafil30$46,312
EliquisApixaban39$44,567
EntrestoSacubitril/Valsartan29$28,751
FarxigaDapagliflozin Propanediol31$27,831
XareltoRivaroxaban25$15,396
Bumetanide13$1,149
Metoprolol Succinate42$722
Digoxin16$510
Losartan Potassium36$375
Sildenafil Citrate17$331
Amiodarone Hcl16$287
Spironolactone42$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Tracleer$84,388$846,79958 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 239 pediatric cardiology providers in California.

Other pediatric cardiology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →